Multiple Manufacturers

PANZYGA

Manufacturer:

Multiple Manufacturers

Panzyga HCPCS:

J1576

HCPCS Code Descriptor:

Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg

Category:

J Code

Panzyga NDCs:

00069-1558-02, 68982-0822-06, 00069-1415-02, 68982-0822-05, 00069-1312-02, 68982-0822-04, 00069-1224-02, 68982-0822-03, 00069-1109-02, 68982-0822-02, 00069-1011-02, 68982-0822-01

Primary Type:

Immunoglobulin

Generic/Specialty Status:

Multi-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

68982-0822-06, 68982-0822-05, 68982-0822-04, 68982-0822-03, 68982-0822-02, 68982-0822-01

About Panzyga:

PANZYGA is a Immunoglobulin drug manufactured by PFIZER INC. and administered via the Intravenous route of administration. The J Code: J1576 is aligned to the drug PANZYGA.

Panzyga is an immunoglobulin medication that works by using human blood containing high levels of antibodies. Panzyga can be used to aid the patient’s immunes system and can also be used to treat certain neurological disorders. This medication is manufactured by Octapharma and Pfizer. The J code: J1576 was aligned to this medication in July of 2023 under the 505(B)(2) pathway. The NDCs aligned to this code were previously aligned to the miscellaneous code for Panzyga: J1599. Patient assistance programs for this medication can be found through Panzyga’s website.

ACCESS PRICING AND MORE BY REGISTERING

J1576 Added Date:

July 1, 2023

J1576 Effective Date:

July 1, 2023

J1576 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Panzyga billing and coding information.
Panzyga patient assistance information can be found through MyPanzyga at the URL: https://www.panzygainfo.com/patient-resources
PANZYGA prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for PANZYGA. Please check back in a few weeks.